Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab

Transplant Infectious Disease

Volumn 15, Issue 3, 2013, Pages 259-267

  Patriarca, F ^a   Medeot, M ^a   Isola, M ^a   Battista, M L ^a   Sperotto, A ^a   Pipan, C ^a   Toffoletti, E ^a   Dozzo, M ^a   Michelutti, A ^a   Gregoraci, G ^a   Geromin, A ^a   Cerno, M ^a   Savignano, C ^b   Rinaldi, C ^b   Barbone, F ^a   Fanin, R ^a  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Allogeneic stem cell transplantation; Anti thymocyte globulin; EBV DNAemia; PTLD; Rituximab; Unrelated donors

Indexed keywords

RITUXIMAB; THYMOCYTE ANTIBODY;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CD4 LYMPHOCYTE COUNT; CHEMOTHERAPY; EPSTEIN BARR VIRUS INFECTION; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTILYMPHOCYTE SERUM; CD4 LYMPHOCYTE COUNT; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; INCIDENCE; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; PROGNOSIS; RISK; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; VIREMIA; YOUNG ADULT;

EID: 84878655369     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12061     Document Type: Article

References (32)

1. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999; 94: 2208-2216.
2. Deeg HJ, Socie G. Malignancies after hematopoietic stem cell transplantation: many questions, some answers. Blood 1998; 91: 1833-1844.
3. Micallef IN, Chhanabhai M, Gascoyne RD, et al. Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience. Bone Marrow Transplant 1998; 22: 9-81.
4. Weinstock DM, Ambrossi GG, Brennan C, Kiehn TE, Jakubowski A. Preemptive diagnosis and treatment of Epstein-Barr virusassociated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant 2006; 37: 539-546.
5. Zutter MM, Martin PJ, Sale GE, et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988; 72: 520-529.
6. van Esser JW, van der Holt B, Meijer E, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBVlymphoproliferative disease following T-cell-depleted SCT. Blood 2001; 98: 972-978.
7. Wilkinson AH, Smith JL, Hunsicker LG, et al. Increased frequency of post-transplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone. Transplantation 1989; 47: 293-296.
8. Beck R, Westdorp I, Jahn G, Schafer H, Kanz L, Einsele H. Detection of Epstein-Barr virus DNA in plasma from patients with lymphoproliferative disease after allogeneic bone marrow or peripheral blood stem cell transplantation. J Clin Microbiol 1999; 37: 3430-3431.
9. Styczynski J, Reusser P, Einsele H, et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 2009; 43 (10): 757-770.
10. Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15: 1628-1633.
11. Reddy P, Ferrara JLM. Immunobiology of acute graft-versus-hostdisease. Blood Rev 2003; 17: 187-194.
12. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institute of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956.
13. Swerdlow SH, Campo E, Harris NL, et al., eds. WHO Classifications of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.
14. Meta CR, Patel NR. Exact logistic regression: theory and examples. Stat Med 1995; 14: 2143-2160.
15. Fine JP, Gray RJ. A proportional hazard model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94 (446): 496-509.
16. Baldanti F, Gatti M, Furione M, et al. Kinetics of Epstein-Barr virus DNA load in different blood compartments of pediatric recipients of T-cell-depleted HLA-haploidentical stem cell transplantation. J Clin Microbiol 2008; 46: 3672-3677.
17. Reddy N, Rezvani K, Barrett AJ, Savani BN. Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients. Biol Blood Marrow Transplant 2011; 17: 591-597.
18. Cesaro S, Pegoraro A, Tridello G, et al. A prospective study on modulation of immunosuppression for Epstein-Barr virus reactivation in pediatric patients who underwent unrelated hematopoietic stem cell transplantation. Transplantation 2010; 89: 1533-1540.
19. Carpenter B, Haque T, Dimopoulou M, et al. Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumabbased conditioning for allogeneic hematopoietic stem cell transplantation. Transplantation 2010; 90: 564-570.
20. Dominietto A, Tedone E, Soracco B, et al. In vivo B-cell depletion with rituximab for alternative donor hematopoietic SCT. Bone Marrow Transplant 2012; 47: 101-106.
21. Peric Z, Cahu X, Chevallier P, et al. Features of Epstein-Barr virus reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation. Leukemia 2011; 25: 932-938.
22. Coppoletta S, Tedone E, Galano B, et al. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 901-907.
23. Faraci M, Caviglia I, Morreale G, et al. Viral-load and Blymphocyte monitoring of EBV reactivation after allogeneic hematopoietic SCT in children. Bone Marrow Transplant 2010; 45: 1052-1055.
24. Ahmad I, Cau NV, Kwan J, et al. Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem cell transplantation. Transplantation 2009; 87: 1240-1245.
25. Landgren O, Gilbert ES, Rizzo D, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 4992-5001.
26. Styczynski J, Einsele H, Gil L, Ljungman P. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis 2009; 11: 383-392.
27. Juvonen E, Aalto SM, Tarkkanen J, et al. High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment. Bone Marrow Transplant 2003; 32: 97-102.
28. Wagner HJ, Cheng YC, Huls MH, et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004; 103: 3979-3981.
29. Pistillo MP, Tazzari PL, Bonifazi F, et al. Detection of a novel specificity (CTLA-4) in ATG/TMG globulins and sera from ATGtreated leukemic patients. Transplantation 2002; 73: 1295-1302.
30. Kim HJ, Min WS, Cho BS, et al. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched unrelated hematopoietic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 2009; 15: 704-717.
31. Siedel MG, Fritsch G, Matthes-Martin S, et al. Antithymocyte globulin pharmacokinetics in pediatric patients after hematopoietic stem cell transplantation. J Pediatr Hematol Oncol 2005; 27: 532-536.
32. van Esser JW, Niesters HGM, van der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic cell transplantation. Blood 2002; 99: 4364-4369.